Mein Warenkorb

FGF basic

FGF basic Molekülinformation

Englischer NameFibroblast growth factor 2Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel3Target-AliasFGF-2,Heparin-binding growth factor 2,Basic fibroblast growth factor,FGFB,bFGF,HBGF-2,FGF2,Fibroblast Growth Factor 2 (Basic),Basic Fibroblast Growth Factor BFGF,Prostatropin,Fibroblast Growth Factor 2
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameFibroblast growth factor 2
Target-AliasFGF-2,Heparin-binding growth factor 2,Basic fibroblast growth factor,FGFB,bFGF,HBGF-2,FGF2,Fibroblast Growth Factor 2 (Basic),Basic Fibroblast Growth Factor BFGF,Prostatropin,Fibroblast Growth Factor 2
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel3
Höchste Forschungs- und EntwicklungsphaseApproved

FGF basic Molekülhintergrund

FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. FGF basic has been isolated from a number of sources, including neural tissue, pituitary, adrenal cortex, corpus luteum, and placenta. This factor contains four cysteine residues, but reduced FGF basic retains full biological activity, indicating that disulfide bonds are not required for this activity. bFGF is a critical component of human embryonic stem cell culture medium; the growth factor is necessary for the cells to remain in an undifferentiated state, although the mechanisms by which it does this are poorly defined. It has been demonstrated to induce gremlin expression which in turn is known to inhibit the induction of differentiation by bone morphogenetic proteins. It is necessary in mouse-feeder cell dependent culture systems, as well as in feeder and serum-free culture systems.

FGF basic Molekülalias

FGF2,BFGF,FGFB,FGF basic,HBGF-2

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Muparfostat sodiumPI-88Phase 3 ClinicalAustralian National UniversityLiver Neoplasms; Skin Melanoma; Solid tumours; Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
RBM-007ID3 (21); APT-F2; RBM-007Phase 2 ClinicalRibomicAchondroplasia; Macular Degeneration
Details
Fibroblast growth factor 2 gene therapy (ID Pharma)SeV-10101; SEV-10101; DVC-10101; BF-30Phase 2 ClinicalDnavecArterial Occlusive Diseases; Intermittent Claudication; Ischemia; Peripheral Arterial Disease; Peripheral arterial occlusive disorders
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
ThalidomideNSC-66847; NSC-527179; K-17; FPF-300; FPF300ApprovedCelgene CorpTalizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, ThaledMainland ChinaLeprosy, Lepromatous; Multiple MyelomaChangzhou Pharmaceutical Factory1982-01-01Xerostomia; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatitis; Primary Myelofibrosis; Osteosarcoma; Cholangitis, Sclerosing; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Epilepsy; Erythema Nodosum; Sarcoma; HIV Wasting Syndrome; Pancreatitis, Chronic; Sarcoma, Ewing; Arachnoiditis; Gastrointestinal Hemorrhage; Retinoblastoma; Prostatic Neoplasms; Endometriosis; Lung Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Myelodysplastic-Myeloproliferative Diseases; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Carcinoma, Hepatocellular; Burning Mouth Syndrome; Stomatitis; Neoplasm Metastasis; Appendiceal Neoplasms; Tuberculosis; Lymphoma, Non-Hodgkin; Angiodysplasia; Pelvic Pain; Glioma; Waldenstrom Macroglobulinemia; Leprosy, Lepromatous; Endometrial Neoplasms; Uterine Neoplasms; Anemia, Sideroblastic; Ovarian Neoplasms; Gastric Antral Vascular Ectasia; Lupus Erythematosus, Discoid; Carc
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns